Emerging as a promising development in the fight against obesity, this medication is generating considerable interest . It combines properties of two recognized GLP-1 receptor agonists, dulaglutide , and an additional glucose-dependent peptide component. Initial patient findings have demonstrated substantial body loss in people with obesity , poten